Cargando…
Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study
BACKGROUND: Currently, only a few retrospective cohort or cross-sectional studies have described the general characteristics of Brazilian patients with classical dermatomyositis (DM). In contrast, we aimed to longitudinally assess a large sample of these patients, and several myositis autoantibodies...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660096/ https://www.ncbi.nlm.nih.gov/pubmed/36371389 http://dx.doi.org/10.1186/s42358-022-00276-x |
_version_ | 1784830350219804672 |
---|---|
author | Truzzi, Natássia Cristina Carboni Hoff, Leonardo Santos Borges, Isabela Bruna Pires de Souza, Fernando Henrique Carlos Shinjo, Samuel Katsuyuki |
author_facet | Truzzi, Natássia Cristina Carboni Hoff, Leonardo Santos Borges, Isabela Bruna Pires de Souza, Fernando Henrique Carlos Shinjo, Samuel Katsuyuki |
author_sort | Truzzi, Natássia Cristina Carboni |
collection | PubMed |
description | BACKGROUND: Currently, only a few retrospective cohort or cross-sectional studies have described the general characteristics of Brazilian patients with classical dermatomyositis (DM). In contrast, we aimed to longitudinally assess a large sample of these patients, and several myositis autoantibodies. METHODS: This single-center longitudinal study included 91 Brazilian adults with defined DM (EULAR/ACR 2017) who underwent follow-up appointments in our tertiary center from 2012 to 2021. Myositis autoantibody analysis was performed using a commercial kit. RESULTS: The mean age of the patients was 47.3 ± 15.4 years, with a predominance of female (67.0%) and White (81.3%) patients. As an initial treatment, 76.9% of the patients received methylprednisolone pulse therapy, 59.3% received intravenous immunoglobulin, and 54.9% received both drugs. The median follow-up duration was 44 months (interquartile 17–67) months. There were 92 severe episodes of infection, and neoplasms were identified in 20 patients (22.0%). Hypertension was identified in 46.2% of patients, whereas diabetes mellitus and myocardial infarction occurred in 19.8% and 4.4%, respectively. Nine patients died during the follow-up. At the last visit, one-third of the patients had disease activity, half had a complete clinical response, and one-fifth were in disease remission. In a univariate logistic regression, anti-aminoacyl-tRNA synthetase antibodies (n = 13) were associated with interstitial lung disease, “mechanic’s hands”, and anti-Ro-52, and had an inverse association with “V”-neck and “shawl” signs. Anti-MDA-5 (n = 10) were associated with male gender, digital ulcers, vasculitis, arthritis, anti-Ro-52, and active disease. Anti-Ro-52 (n = 26) were associated with “mechanics’ hands”, arthritis, interstitial lung disease, anti-tRNA synthetases, and anti-MDA-5. No association was found for anti-Mi-2 (n = 10). CONCLUSIONS: This study shows the general profile of a significant sample of Brazilian patients with DM as well as the association of some antibodies with clinical and laboratory manifestations of this myositis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42358-022-00276-x. |
format | Online Article Text |
id | pubmed-9660096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96600962022-11-14 Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study Truzzi, Natássia Cristina Carboni Hoff, Leonardo Santos Borges, Isabela Bruna Pires de Souza, Fernando Henrique Carlos Shinjo, Samuel Katsuyuki Adv Rheumatol Research BACKGROUND: Currently, only a few retrospective cohort or cross-sectional studies have described the general characteristics of Brazilian patients with classical dermatomyositis (DM). In contrast, we aimed to longitudinally assess a large sample of these patients, and several myositis autoantibodies. METHODS: This single-center longitudinal study included 91 Brazilian adults with defined DM (EULAR/ACR 2017) who underwent follow-up appointments in our tertiary center from 2012 to 2021. Myositis autoantibody analysis was performed using a commercial kit. RESULTS: The mean age of the patients was 47.3 ± 15.4 years, with a predominance of female (67.0%) and White (81.3%) patients. As an initial treatment, 76.9% of the patients received methylprednisolone pulse therapy, 59.3% received intravenous immunoglobulin, and 54.9% received both drugs. The median follow-up duration was 44 months (interquartile 17–67) months. There were 92 severe episodes of infection, and neoplasms were identified in 20 patients (22.0%). Hypertension was identified in 46.2% of patients, whereas diabetes mellitus and myocardial infarction occurred in 19.8% and 4.4%, respectively. Nine patients died during the follow-up. At the last visit, one-third of the patients had disease activity, half had a complete clinical response, and one-fifth were in disease remission. In a univariate logistic regression, anti-aminoacyl-tRNA synthetase antibodies (n = 13) were associated with interstitial lung disease, “mechanic’s hands”, and anti-Ro-52, and had an inverse association with “V”-neck and “shawl” signs. Anti-MDA-5 (n = 10) were associated with male gender, digital ulcers, vasculitis, arthritis, anti-Ro-52, and active disease. Anti-Ro-52 (n = 26) were associated with “mechanics’ hands”, arthritis, interstitial lung disease, anti-tRNA synthetases, and anti-MDA-5. No association was found for anti-Mi-2 (n = 10). CONCLUSIONS: This study shows the general profile of a significant sample of Brazilian patients with DM as well as the association of some antibodies with clinical and laboratory manifestations of this myositis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42358-022-00276-x. BioMed Central 2022-11-12 2022 /pmc/articles/PMC9660096/ /pubmed/36371389 http://dx.doi.org/10.1186/s42358-022-00276-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Truzzi, Natássia Cristina Carboni Hoff, Leonardo Santos Borges, Isabela Bruna Pires de Souza, Fernando Henrique Carlos Shinjo, Samuel Katsuyuki Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study |
title | Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study |
title_full | Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study |
title_fullStr | Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study |
title_full_unstemmed | Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study |
title_short | Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study |
title_sort | clinical manifestations, outcomes, and antibody profile of brazilian adult patients with dermatomyositis: a single-center longitudinal study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660096/ https://www.ncbi.nlm.nih.gov/pubmed/36371389 http://dx.doi.org/10.1186/s42358-022-00276-x |
work_keys_str_mv | AT truzzinatassiacristinacarboni clinicalmanifestationsoutcomesandantibodyprofileofbrazilianadultpatientswithdermatomyositisasinglecenterlongitudinalstudy AT hoffleonardosantos clinicalmanifestationsoutcomesandantibodyprofileofbrazilianadultpatientswithdermatomyositisasinglecenterlongitudinalstudy AT borgesisabelabrunapires clinicalmanifestationsoutcomesandantibodyprofileofbrazilianadultpatientswithdermatomyositisasinglecenterlongitudinalstudy AT desouzafernandohenriquecarlos clinicalmanifestationsoutcomesandantibodyprofileofbrazilianadultpatientswithdermatomyositisasinglecenterlongitudinalstudy AT shinjosamuelkatsuyuki clinicalmanifestationsoutcomesandantibodyprofileofbrazilianadultpatientswithdermatomyositisasinglecenterlongitudinalstudy |